Welcome

Biomarkerregistry.org is a tumor biomarker studies registry about planned tumor biomarker studies and previously conducted tumor biomarker studies.


Biomarkerregistry.org offers basic information including the clinical trial summary and identifier, patient characteristics, listing of all biomarkers tested as well as the technology used, the main results and the contact identifiers.



More about us »

Supported by WIN Consortium

Recently added biomarker studies

Title / Author Biomarker
MINDACT : Microarray In Node-negative and 1 to 3 positive lymph node Disease may Avoid ChemoTherapy
Emiel J. T. Rutgers/Martine J. Piccart/Fatima Cardoso
ER/PgR/HER2/KI-67
Simultaneous Study of Docetaxel Based Antracycline Free Adjuvant Treatment Evaluation, as well as Life Style Intervention Strategies (SUCCESS C)
Prof. Dr. Wolfgang Janni
CK19mRNA-positive CTCs, fasting insulin, adiponectin, leptin, potentially other adipokines
Role of Immunogenic cell death markers (HMGB1 and LC3) in the response to anthracyclines-based chemotherapy in breast cancers
UNICANCER
HMGB1 (high mobility group box 1 protein) and LC3-II, the conjugated form of the microtubule-associated protein 1 light chain 3 (LC3) used as a marker for monitoring the autophagic process
A phase III study evaluating the benefit of docetaxel given sequentially with FEC 100 chemotherapy treatment in axillary lymph node-positive early breast cancer patients
Henri Roché
A catenin
ECE1 and PZP SNPs to predict efficacy of neoadjuvant chemotherapy
G. Von Minckwitz
SNPs ECE1 and PZP (rs1076669 and rs 2277413)